Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis

Yu Chen Lee, Jung Kang Jin, Chien Jui Cheng, Chih Fen Huang, Jian H. Song, Miao Huang, Wells S. Brown, Sui Zhang, Li Yuan Yu-Lee, Edward T. Yeh, Bradley W. McIntyre, Christopher J. Logothetis, Gary E. Gallick, Sue Hwa Lin

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Disseminated prostate cancer cells must survive in circulation for metastasis to occur. Mechanisms by which these cells survive are not well understood. By immunohistochemistry of human tissues, we found that levels of β1 integrins and integrin-induced autophosphorylation of FAK (pFAK-Y397) are increased in prostate cancer cells in primary prostate cancer and lymph node metastases, suggesting that β1 integrin activation occurs in metastatic progression of prostate cancer. A conformation-sensitive antibody, 9EG7, was used to examine β1 integrin activation. We found that β1 integrins are constitutively activated in highly metastatic PC3 and PC3- mm2 cells, with less activation in low metastatic LNCaP and C4-2B4 cells. Increased β1 integrin activation as well as the anoikis resistance in prostate cancer cells correlated with metastatic potential in vivo. Knockdown of β1 integrin abrogated anoikis resistance in PC3-mm2 cells. In agreement with β1 integrin activation, PC3-mm2 cells strongly adhered to type I collagen and fibronectin, a process inhibited by the β1 integrinneutralizing antibody mAb 33B6. mAb 33B6 also inhibited the phosphorylation of β1 integrin downstream effectors, focal adhesion kinase (FAK) and AKT, leading to a 3-fold increase in PC3-mm2 apoptosis. Systemic delivery of mAb 33B6 suppressed spontaneous metastasis of PC3-mm2 from the prostate to distant lymph nodes following intraprostatic injection and suppressed metastasis of PC3-mm2 to multiple organs following intracardiac injection. Thus, constitutively activated β1 integrins play a role in survival of PC3-mm2 cells in circulation and represent a potential target for metastasis prevention.

Original languageEnglish
Pages (from-to)405-417
Number of pages13
JournalMolecular Cancer Research
Volume11
Issue number4
DOIs
Publication statusPublished - Apr 2013

Fingerprint

Integrins
Prostatic Neoplasms
Neoplasm Metastasis
Anoikis
Focal Adhesion Protein-Tyrosine Kinases
Lymph Nodes
Injections
Antibodies
Collagen Type I
Fibronectins
Prostate
Immunohistochemistry
Phosphorylation
Apoptosis
Survival

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Oncology

Cite this

Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis. / Lee, Yu Chen; Jin, Jung Kang; Cheng, Chien Jui; Huang, Chih Fen; Song, Jian H.; Huang, Miao; Brown, Wells S.; Zhang, Sui; Yu-Lee, Li Yuan; Yeh, Edward T.; McIntyre, Bradley W.; Logothetis, Christopher J.; Gallick, Gary E.; Lin, Sue Hwa.

In: Molecular Cancer Research, Vol. 11, No. 4, 04.2013, p. 405-417.

Research output: Contribution to journalArticle

Lee, YC, Jin, JK, Cheng, CJ, Huang, CF, Song, JH, Huang, M, Brown, WS, Zhang, S, Yu-Lee, LY, Yeh, ET, McIntyre, BW, Logothetis, CJ, Gallick, GE & Lin, SH 2013, 'Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis', Molecular Cancer Research, vol. 11, no. 4, pp. 405-417. https://doi.org/10.1158/1541-7786.MCR-12-0551
Lee, Yu Chen ; Jin, Jung Kang ; Cheng, Chien Jui ; Huang, Chih Fen ; Song, Jian H. ; Huang, Miao ; Brown, Wells S. ; Zhang, Sui ; Yu-Lee, Li Yuan ; Yeh, Edward T. ; McIntyre, Bradley W. ; Logothetis, Christopher J. ; Gallick, Gary E. ; Lin, Sue Hwa. / Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis. In: Molecular Cancer Research. 2013 ; Vol. 11, No. 4. pp. 405-417.
@article{051cfcfe1c4143eda10f651e60d6e764,
title = "Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis",
abstract = "Disseminated prostate cancer cells must survive in circulation for metastasis to occur. Mechanisms by which these cells survive are not well understood. By immunohistochemistry of human tissues, we found that levels of β1 integrins and integrin-induced autophosphorylation of FAK (pFAK-Y397) are increased in prostate cancer cells in primary prostate cancer and lymph node metastases, suggesting that β1 integrin activation occurs in metastatic progression of prostate cancer. A conformation-sensitive antibody, 9EG7, was used to examine β1 integrin activation. We found that β1 integrins are constitutively activated in highly metastatic PC3 and PC3- mm2 cells, with less activation in low metastatic LNCaP and C4-2B4 cells. Increased β1 integrin activation as well as the anoikis resistance in prostate cancer cells correlated with metastatic potential in vivo. Knockdown of β1 integrin abrogated anoikis resistance in PC3-mm2 cells. In agreement with β1 integrin activation, PC3-mm2 cells strongly adhered to type I collagen and fibronectin, a process inhibited by the β1 integrinneutralizing antibody mAb 33B6. mAb 33B6 also inhibited the phosphorylation of β1 integrin downstream effectors, focal adhesion kinase (FAK) and AKT, leading to a 3-fold increase in PC3-mm2 apoptosis. Systemic delivery of mAb 33B6 suppressed spontaneous metastasis of PC3-mm2 from the prostate to distant lymph nodes following intraprostatic injection and suppressed metastasis of PC3-mm2 to multiple organs following intracardiac injection. Thus, constitutively activated β1 integrins play a role in survival of PC3-mm2 cells in circulation and represent a potential target for metastasis prevention.",
author = "Lee, {Yu Chen} and Jin, {Jung Kang} and Cheng, {Chien Jui} and Huang, {Chih Fen} and Song, {Jian H.} and Miao Huang and Brown, {Wells S.} and Sui Zhang and Yu-Lee, {Li Yuan} and Yeh, {Edward T.} and McIntyre, {Bradley W.} and Logothetis, {Christopher J.} and Gallick, {Gary E.} and Lin, {Sue Hwa}",
year = "2013",
month = "4",
doi = "10.1158/1541-7786.MCR-12-0551",
language = "English",
volume = "11",
pages = "405--417",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "4",

}

TY - JOUR

T1 - Targeting constitutively activated β1 integrins inhibits prostate cancer metastasis

AU - Lee, Yu Chen

AU - Jin, Jung Kang

AU - Cheng, Chien Jui

AU - Huang, Chih Fen

AU - Song, Jian H.

AU - Huang, Miao

AU - Brown, Wells S.

AU - Zhang, Sui

AU - Yu-Lee, Li Yuan

AU - Yeh, Edward T.

AU - McIntyre, Bradley W.

AU - Logothetis, Christopher J.

AU - Gallick, Gary E.

AU - Lin, Sue Hwa

PY - 2013/4

Y1 - 2013/4

N2 - Disseminated prostate cancer cells must survive in circulation for metastasis to occur. Mechanisms by which these cells survive are not well understood. By immunohistochemistry of human tissues, we found that levels of β1 integrins and integrin-induced autophosphorylation of FAK (pFAK-Y397) are increased in prostate cancer cells in primary prostate cancer and lymph node metastases, suggesting that β1 integrin activation occurs in metastatic progression of prostate cancer. A conformation-sensitive antibody, 9EG7, was used to examine β1 integrin activation. We found that β1 integrins are constitutively activated in highly metastatic PC3 and PC3- mm2 cells, with less activation in low metastatic LNCaP and C4-2B4 cells. Increased β1 integrin activation as well as the anoikis resistance in prostate cancer cells correlated with metastatic potential in vivo. Knockdown of β1 integrin abrogated anoikis resistance in PC3-mm2 cells. In agreement with β1 integrin activation, PC3-mm2 cells strongly adhered to type I collagen and fibronectin, a process inhibited by the β1 integrinneutralizing antibody mAb 33B6. mAb 33B6 also inhibited the phosphorylation of β1 integrin downstream effectors, focal adhesion kinase (FAK) and AKT, leading to a 3-fold increase in PC3-mm2 apoptosis. Systemic delivery of mAb 33B6 suppressed spontaneous metastasis of PC3-mm2 from the prostate to distant lymph nodes following intraprostatic injection and suppressed metastasis of PC3-mm2 to multiple organs following intracardiac injection. Thus, constitutively activated β1 integrins play a role in survival of PC3-mm2 cells in circulation and represent a potential target for metastasis prevention.

AB - Disseminated prostate cancer cells must survive in circulation for metastasis to occur. Mechanisms by which these cells survive are not well understood. By immunohistochemistry of human tissues, we found that levels of β1 integrins and integrin-induced autophosphorylation of FAK (pFAK-Y397) are increased in prostate cancer cells in primary prostate cancer and lymph node metastases, suggesting that β1 integrin activation occurs in metastatic progression of prostate cancer. A conformation-sensitive antibody, 9EG7, was used to examine β1 integrin activation. We found that β1 integrins are constitutively activated in highly metastatic PC3 and PC3- mm2 cells, with less activation in low metastatic LNCaP and C4-2B4 cells. Increased β1 integrin activation as well as the anoikis resistance in prostate cancer cells correlated with metastatic potential in vivo. Knockdown of β1 integrin abrogated anoikis resistance in PC3-mm2 cells. In agreement with β1 integrin activation, PC3-mm2 cells strongly adhered to type I collagen and fibronectin, a process inhibited by the β1 integrinneutralizing antibody mAb 33B6. mAb 33B6 also inhibited the phosphorylation of β1 integrin downstream effectors, focal adhesion kinase (FAK) and AKT, leading to a 3-fold increase in PC3-mm2 apoptosis. Systemic delivery of mAb 33B6 suppressed spontaneous metastasis of PC3-mm2 from the prostate to distant lymph nodes following intraprostatic injection and suppressed metastasis of PC3-mm2 to multiple organs following intracardiac injection. Thus, constitutively activated β1 integrins play a role in survival of PC3-mm2 cells in circulation and represent a potential target for metastasis prevention.

UR - http://www.scopus.com/inward/record.url?scp=84876586639&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876586639&partnerID=8YFLogxK

U2 - 10.1158/1541-7786.MCR-12-0551

DO - 10.1158/1541-7786.MCR-12-0551

M3 - Article

VL - 11

SP - 405

EP - 417

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 4

ER -